XML 86 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
Note 14 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Licensing revenue $ 850 $ 0
Research and development expense 42,342 38,120
General and administrative expense 15,133 12,243
Other income 7,250 7,869
Net loss (49,375) (42,494)
Personnel [Member]    
Research and development expense 9,918 7,568
General and administrative expense 3,818 2,623
General [Member]    
Research and development expense 3,965 3,647
General and administrative expense 4,661 4,054
Tovecimig [Member]    
Research and development expense 23,177 21,824
CTX-471 [Member]    
Research and development expense 2,879 2,846
CTX-8371 [Member]    
Research and development expense 2,403 2,235
Stock Based Compensation [Member]    
General and administrative expense $ 6,654 $ 5,566